Duration of anticoagulation for venous thromboembolism.

Abstract:

:The duration of oral anticoagulant therapy for venous thromboembolism (VTE) depends on the risk of recurrence if treatment is stopped and the risk of bleeding if treatment is continued. If the risk of recurrence is low (e.g., thrombosis provoked by a major reversible risk factor such as surgery), 3 months of treatment is usually adequate. If the risk of recurrence is high (unprovoked "idiopathic" VTE or associated with a non-reversible risk factor such as active cancer), 6 months or indefinite anticoagulant therapy is indicated. The presence of malignancy, an antiphospholipid antibody, and other selected thrombophilic states suggests more prolonged therapy, whereas isolated distal deep vein thrombosis, high risk of bleeding, and patient preference suggest a shorter course of treatment.

journal_name

J Thromb Thrombolysis

authors

Kearon C

doi

10.1023/a:1012790511790

subject

Has Abstract

pub_date

2001-09-01 00:00:00

pages

59-65

issue

1

eissn

0929-5305

issn

1573-742X

journal_volume

12

pub_type

杂志文章,评审
  • The pharmacology of novel oral anticoagulants.

    abstract::Anticoagulation for the prevention of stroke is an important aspect of the management of atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke i...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-013-0967-z

    authors: DeWald TA,Becker RC

    更新日期:2014-01-01 00:00:00

  • Microbubble potentiated transcranial duplex ultrasound enhances IV thrombolysis in acute stroke.

    abstract:BACKGROUND:We studied whether 2 MHz transcranial color-coded duplex ultrasound (TCCD), combined with a second generation ECA, accelerate IV rtPA-thrombolysis in the acute phase of MCA stroke more than TCCD monitoring alone. METHODS:Non-randomized acute MCA stroke patients undergoing IV rtPA-thrombolysis and 2 MHZ-TCCD...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-007-0044-6

    authors: Perren F,Loulidi J,Poglia D,Landis T,Sztajzel R

    更新日期:2008-04-01 00:00:00

  • Performance of the right ventricular outflow tract/aortic diameter as a novel predictor of risk in patients with acute pulmonary embolism.

    abstract::Right ventricular (RV) enlargement, determined via the ratio of the right to left ventricular diameters (RV/LV) by CT imaging is used to classify the severity of acute pulmonary embolism (PE) and impacts treatment decisions. The RV/LV ratio may be an unreliable marker of RV dysfunction, due in part to the complex RV g...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-02021-6

    authors: Marginean A,Putnam A,Hirai T,Serritella A,Besser SA,Lee M,Friant J,Blair J,Shah A,Nathan S,Chung J,Paul J

    更新日期:2020-07-01 00:00:00

  • Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study.

    abstract:OBJECTIVE:We aimed to determine the relative level of platelet inhibition achieved with low-dose aspirin (81 mg daily) compared with a very low-dose (100 mg every other day). BACKGROUND:The Womens Health Study (WHS) found that a dose of 100 mg every other day of aspirin provided protection against stroke as primary pr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-008-0262-6

    authors: Swaim L,Hillman RS

    更新日期:2009-07-01 00:00:00

  • Thrombolytic therapy in pregnancy.

    abstract::Pregnancy due to its physiological changes is a procoagulant state. The rate of cardiac valve prosthesis thrombosis, deep venous thrombosis and pulmonary embolism are all increased. Thrombolytic therapy with tissue plasminogen activator (rt-PA) is an approved therapy for ischemic stroke, myocardial infarction, pulmona...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-006-5709-z

    authors: Leonhardt G,Gaul C,Nietsch HH,Buerke M,Schleussner E

    更新日期:2006-06-01 00:00:00

  • Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves.

    abstract::Patients with mechanical heart valves (MHV) undergoing invasive procedures often receive periprocedural bridging with low-molecular-weight heparin (LMWH). The bridging strategies used in real-life and the predictors for bleeding and thrombosis are not well studied. We retrospectively assessed patients with MHV that un...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-015-1216-4

    authors: Schulman JM,Majeed A,Mattsson E,Schulman S,Holmström M,Ågren A

    更新日期:2015-11-01 00:00:00

  • Impact of gender on immature platelet count and its relationship with coronary artery disease.

    abstract::The impact of platelet parameters on the cardiovascular risk is still debated. Gender differences in platelet volume indexes and turnover have been previously reported, potentially conditioning their role in the development of coronary artery disease (CAD). However, few studies have addressed, so far, the impact of ge...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02080-0

    authors: Negro F,Verdoia M,Tonon F,Nardin M,Kedhi E,De Luca G,Novara Atherosclerosis Study Group (NAS).

    更新日期:2020-05-01 00:00:00

  • Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty.

    abstract::Time to treatment with thrombolytic therapy has been recognized as an important factor in the treatment of patients with acute myocardial infarction: By restoring infarct-related artery patency earlier, clinical outcome is improved. Of the several components of time delay between the onset of pain to opening of the ar...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF00181669

    authors: Cannon CP

    更新日期:1996-01-01 00:00:00

  • Interhospital transfer on intravenous thrombolysis in patients with acute ischemic stroke in three chinese municipal stroke centers.

    abstract::We included acute ischemic stroke (AIS) patients who received recombinant tissue plasminogen activator (rt-PA) at three stroke centers via either interhospital transfer or direct presentation and compared the clinical outcomes and time metrics to analyze the impact of interhospital transfer on intravenous thrombolysis...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-019-01912-y

    authors: Ding Y,Ji Z,Ma L,Zhai T,Gu Z,Niu J,Liu Y

    更新日期:2019-11-01 00:00:00

  • Outpatient Therapy of Deep Vein Thrombosis.

    abstract::The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1013232803747

    authors: Pineo GF,Hull RD

    更新日期:1998-01-01 00:00:00

  • Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients.

    abstract::A perceived increased risk of bleeding is one of the most frequent reasons for withholding anticoagulation for stroke prevention in atrial fibrillation (AF). We previously conducted a randomized controlled trial of alert-based computerized decision support to increase prescription of anticoagulation in hospitalized pa...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02296-0

    authors: Piazza G,Hurwitz S,Carroll B,Goldhaber SZ

    更新日期:2020-09-30 00:00:00

  • Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

    abstract::Point-of-care whole blood coagulation tests are critical in the management of patients who undergo percutaneous coronary intervention. The Hemochron and HemoTec devices have been traditionally used to measure the activated clotting time (ACT) in the cardiac catheterization laboratory. The heparin management test (HMT)...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1011908803939

    authors: Tsimikas S,Beyer R,Hassankhani A

    更新日期:2001-05-01 00:00:00

  • Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.

    abstract::Half of patients with atrial fibrillation (AF) and elevated stroke risk do not receive anticoagulation (AC). Explanations for undertreatment may relate to provider lack of confidence with or knowledge of the CHA2DS2-VASc stroke calculator, unfamiliarity with direct oral anticoagulants (DOACs), or uncertainty about use...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01950-6

    authors: Amroze A,Mazor K,Crawford S,O'Day K,McManus DD,Kapoor A

    更新日期:2019-11-01 00:00:00

  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study.

    abstract::The relation of device related thrombosis (DRT) and major bleeding after left atrial appendage closure (LAAC) to laboratory thrombosis and hemostasis markers has not been studied. We performed a prospective case control study to identify clinical characteristics and laboratory markers in patients who developed DRT and...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02205-5

    authors: Sherwood M,Bliden KP,Ilkhanoff L,Venkataraman G,Strickberger A,Yazdani S,McSwain R,Rashid H,Navarese EP,Plummer T,Batchelor W,Chaudhary R,Tantry US,Gurbel PA

    更新日期:2020-10-01 00:00:00

  • Bleeding complications in venous thrombosis patients on well-managed warfarin.

    abstract::Anticoagulation treatment is effective in preventing both death and recurrence in patients with venous thromboembolism (VTE), but at the same time confers a substantial risk of bleeding complications. The aim of this study was to examine the rate of and predictors for bleeding complications in VTE patients on warfarin...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-015-1305-4

    authors: Sandén P,Renlund H,Svensson PJ,Själander A

    更新日期:2016-02-01 00:00:00

  • Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry.

    abstract::The optimal antithrombotic therapy for patients undergoing TAVI with concomitant indication for oral anticoagulation remains unclear. In this high-risk population group, there is a paucity of data with regards to the use of DOACs. In the present study we compared long-term clinical outcomes of TAVI patients requiring ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01968-w

    authors: Kalogeras K,Jabbour RJ,Ruparelia N,Watson S,Kabir T,Naganuma T,Vavuranakis M,Nakamura S,Malik IS,Mikhail G,Dalby M,Panoulas V

    更新日期:2020-07-01 00:00:00

  • Eptifibatide-induced thrombocytopenia.

    abstract::Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical litera...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0166-x

    authors: Refaat M,Smith AJ,Edmundowicz D

    更新日期:2008-04-01 00:00:00

  • Comparison of clinical performance of four gastrointestinal bleeding risk scores in Chinese patients with atrial fibrillation receiving oral anticoagulants.

    abstract::Gastrointestinal bleeding is the most common bleeding complication during anticoagulant therapy. A reliable bleeding risk score can help the clinician assess risk of bleeding in individual patients and select the anticoagulant regimen. This study retrospectively analyzed the data of patients with atrial fibrillation w...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02152-1

    authors: Lv MN,Zheng XC,Zhang HQ,Xu FD,Wu TT,Chen WJ,Xia XT,Fu JL,Jiang SJ,Zhang JH

    更新日期:2021-01-01 00:00:00

  • Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis.

    abstract::No study investigated the possible detrimental effect of stress hyperglycemia on patients affected acute ischemic stroke (AIS) undergoing intravenous thrombolysis (IVT). A new index, the glucose-to-glycated hemoglobin ratio (GAR), has been developed for assessing stress hyperglycemia. We retrospectively analyzed data ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02252-y

    authors: Merlino G,Smeralda C,Gigli GL,Lorenzut S,Pez S,Surcinelli A,Marini A,Valente M

    更新日期:2020-08-24 00:00:00

  • Newer anticoagulants in 2009.

    abstract::Several newer anticoagulants are under clinical development. Recently two of them, Dabigatran etexilate/Pradaxa. and Rivaroxaban/Xarelto obtained marketing authorization in Europe and Canada for the prevention of thromboembolic events following major orthopedic surgery such as total hip and knee replacement. The resul...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-009-0392-5

    authors: Samama MM,Gerotziafas GT

    更新日期:2010-01-01 00:00:00

  • The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

    abstract::The postthrombotic syndrome (PTS) is the most common complication of deep venous thrombosis (DVT) yet has received little attention from clinicians and researchers. Clinically, PTS is characterized by chronic pain, swelling, heaviness and other signs in the affected limb. In severe cases, venous ulcers may develop. PT...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-006-5574-9

    authors: Kahn SR

    更新日期:2006-02-01 00:00:00

  • Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome.

    abstract::Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1747-6

    authors: Ratzon R,Tamir S,Friehmann T,Livneh N,Dudnik E,Rozental A,Hamburger-Avnery O,Pereg D,Derazne E,Brenner B,Raanani P,Ten Cate H,Spectre G,Leader A

    更新日期:2019-01-01 00:00:00

  • Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.

    abstract::Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-005-0942-4

    authors: Harenberg J,Jörg I,Fenyvesi T,Piazolo L

    更新日期:2005-02-01 00:00:00

  • Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

    abstract::Among atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), rivaroxaban with background antiplatelet therapy significantly reduced the first occurrence of bleeding compared to triple therapy with warfarin. This study hypothesized that total bleeding events, including those beyond the f...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-018-1703-5

    authors: Chi G,Yee MK,Kalayci A,Kerneis M,AlKhalfan F,Mehran R,Bode C,Halperin JL,Verheugt FWA,Wildgoose P,van Eickels M,Lip GYH,Cohen M,Peterson ED,Fox KAA,Gibson CM

    更新日期:2018-10-01 00:00:00

  • Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

    abstract::A cardiocerebral ischemic attack (CCI) or a concurrent acute ischemic stroke (AIS) and myocardial infarction (AMI) is a severe event with no clear recommendations for ideal management because of the rarity of the scenario. The narrow time window for treatment and complexity of the treatment decision puts immense press...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-017-1484-2

    authors: Yeo LLL,Andersson T,Yee KW,Tan BYQ,Paliwal P,Gopinathan A,Nadarajah M,Ting E,Teoh HL,Cherian R,Lundström E,Tay ELW,Sharma VK

    更新日期:2017-07-01 00:00:00

  • Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.

    abstract::Apixaban is effective and safe for preventing stroke, and its usage has increased exponentially in recent years. However, data concerning the therapeutic range of apixaban is limited. This study determined the trough and peak levels of apixaban-specific anti-factor Xa activity (AFXaA) in acute ischemic stroke patients...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1590-1

    authors: Shin H,Cho MC,Kim RB,Kim CH,Choi NC,Kim SK,Koh EH

    更新日期:2018-02-01 00:00:00

  • Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review.

    abstract::The risk benefit decision in providing anticoagulation for patients with brain metastases is amongst the most difficult decisions faced by clinicians. The purpose of our study was to evaluate both the risk of intracerebral hemorrhage (ICH) associated with anticoagulation therapy and the effect of anticoagulation on su...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s11239-017-1536-7

    authors: Hunter BD,Minichiello T,Bent S

    更新日期:2017-10-01 00:00:00

  • Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents.

    abstract:BACKGROUND:Early change in local intracoronary hemostasis following drug-eluting (DES) and bare metal stent (BMS) implantation has never been assessed in stable angina patients. METHODS:Markers of local platelet activation (soluble glycoprotein V [sGPV] and P-Selectin [CD62P]), coagulation activation (tissue factor [T...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-008-0266-2

    authors: Mahemuti A,Meneveau N,Seronde MF,Schiele F,Descotes-Genon V,Ecarnot F,Blonde MC,Mercier M,Racadot E,Bassand JP

    更新日期:2009-10-01 00:00:00

  • Embolic events caused by aortic thrombi: an underestimated entity?

    abstract::Stroke and other thromboembolic events are mainly caused by emboli from heart, aorta and other arteries. In this paper we describe a group of 5 middle-aged patients suffering from emboli caused by large thrombi in the aorta. Since the development of giant thrombi under high flow conditions in the aorta is a pathophysi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-012-0775-x

    authors: Stoevesandt D,Klempt C,Scheubel R,Herr W,Hettwer S,Werdan K,Silber RE,Kraya T,Thews O,Schlitt A

    更新日期:2013-02-01 00:00:00

  • Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

    abstract::Warfarin is the most widely prescribed oral anticoagulant, but large interindividual variations exist in the dose required to achieve comparable therapeutic effects. Several clinical and genetic variables have been identified that influence warfarin dosing. However, interactions between genotype and nutrition remain u...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0978-9

    authors: Saito R,Takeda K,Yamamoto K,Nakagawa A,Aoki H,Fujibayashi K,Wakasa M,Motoyama A,Iwadare M,Ishida R,Fujioka N,Tsuchiya T,Akao H,Kawai Y,Kitayama M,Kajinami K

    更新日期:2014-07-01 00:00:00